Celldex Therapeutics
CLDX
145 hedge funds and large institutions have $319M invested in Celldex Therapeutics in 2016 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 51 increasing their positions, 50 reducing their positions, and 46 closing their positions.
8% more call options, than puts
Call options by funds: $3.97M | Put options by funds: $3.68M
2% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 50
15% less funds holding
Funds holding: 171 → 145 (-26)
54% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 46
77% less capital invested
Capital invested by funds: $1.39B → $319M (-$1.07B)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$39.4M |
| 2 |
Millennium Management
New York
|
+$16.8M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$6.84M |
| 4 |
Renaissance Technologies
New York
|
+$6.1M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$5.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$35.2M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$17.8M |
| 3 |
CCI
Columbus Circle Investors
|
-$10.3M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$9.83M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$8.7M |
CLDX Hedge Fund Activity: Q1 2016 in Review
145 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2016, worth a combined $319M — down 77% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of CLDX and 21 opened new positions — a net loss of 25 holders — while 50 trimmed existing stakes and 51 added.
The largest buyer was State Street, adding an estimated $39.4M. The largest seller was First Trust Advisors, cutting an estimated $35.2M.
- 145 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2016, down from 171 in Q4 2015.
- Funds reported $319M of Celldex Therapeutics stock for Q1 2016, down 77% quarter-over-quarter.
- 21 funds opened new Celldex Therapeutics positions in Q1 2016 and 46 closed out, a net change of -25 holders.
- The largest Celldex Therapeutics buyer in Q1 2016 was State Street, an estimated $39.4M added.
- The largest Celldex Therapeutics seller in Q1 2016 was First Trust Advisors, an estimated $35.2M sold.
Based on aggregated 13F filings for Q1 2016.